Financial Data and Key Metrics Changes - Revenue for Q3 2025 reached nearly $35 million, with adjusted EBITDA at $11 million, reflecting an 11% year-over-year growth [4][12] - Total Recurring Contract Value (TRCV) rose 8% year-over-year to $142 million, marking the strongest growth since 2020 [4][12] - Adjusted EBITDA margin expanded over four percentage points from Q3 2024 to 31% [13] Business Line Data and Key Metrics Changes - The company secured multiple significant deals, including a TRCV expansion exceeding $1 million with a top 50 health system and additional nearly $1 million cross-sells with top 100 health systems [5] - Customer retention improved, with TRCV losses and downsells reduced by nearly 50% over the past year [5] - The net retention rate reached its highest level since 2020, driven by strong cross-sell and upsell activities [6] Market Data and Key Metrics Changes - The U.S. healthcare landscape is evolving, characterized by shifting consumer expectations, regulatory complexity, workforce challenges, and financial pressures [6] - NRC Health's market opportunity is substantial, as healthcare organizations need to connect deeply with the people they serve [6] Company Strategy and Development Direction - NRC Health's strategy focuses on three core pillars: insights, engagement, and enablement, which are essential for driving measurable improvements in healthcare outcomes [9] - The company aims to modernize its technology platform and evolve its go-to-market model to accelerate growth and enhance customer partnerships [10] - The leadership team is being strengthened, with the recent addition of a new CFO, Shane Harrison, who brings extensive experience in finance and strategy [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in NRC Health's growth opportunities and the relevance of its value proposition in the current healthcare environment [6][16] - The company is committed to a disciplined approach to capital allocation, balancing dividends and share repurchases with strategic investments [14] Other Important Information - The company repurchased 618,000 shares for $9.3 million, reducing the weighted average fully diluted share count by 7% year-over-year [13] - A quarterly dividend of $0.12 per share was paid, with a 33% increase announced to $0.16 per share, payable in January [14] Summary of Q&A Session - No specific questions or answers were documented in the provided content, thus this section is not applicable.